Education
About Us
Working with TipRanks
Follow Us
Takeda Pharmaceutical Co (TKPHF)
:TKPHF
RESEARCH TOOLSreports
TKPHF Stock Chart & Stats
Day’s Range― - ―
52-Week Range$23.90 - $32.85
Previous CloseN/A
Volume20.35K
Average Volume (3M)45.12K
Market Cap
$45.61B
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)44.0
Beta-0.13
Next Earnings
Oct 30, 2025EPS Estimate
0.3Next Dividend Ex-Date
Sep 29, 2025Dividend Yield4.87%
Share Statistics
EPS (TTM)0.53
Shares Outstanding1,590,962,600
10 Day Avg. Volume121,141
30 Day Avg. Volume45,117
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.00
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$34.24Price Target Upside27.76% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Bulls Say, Bears Say
Bulls Say
Clinical TrialsOral OX2R agonist oveporexton meets primary endpoints in two studies, showcasing its efficacy and potential for approval.
Future RevenueThe company estimates peak sales of zasocitinib, oveporexton, and rusfertide to potentially reach significant amounts in the billions, indicating strong future revenue potential.
Market PotentialTakeda disclosed projections that rusfertide peak sales could reach $1-2bn, indicating strong market potential.
Bears Say
Drug Pricing PoliciesRisks are associated with US drug price policy, which has not been accounted for in the earnings estimates.
Financial ImpactThe US’s 340B program and Medicare Part D redesign are estimated to have a significant financial impact on Takeda, totaling JPY130Bn for FY2025.
Patent ExpirationVyvanse going off patent will have long-term effects, impacting the company's performance.
Takeda Pharmaceutical Co News
TKPHF FAQ
What was Takeda Pharmaceutical Co ’s price range in the past 12 months?
Takeda Pharmaceutical Co lowest stock price was $23.90 and its highest was $32.85 in the past 12 months.
What is Takeda Pharmaceutical Co ’s market cap?
Takeda Pharmaceutical Co ’s market cap is $45.61B.
When is Takeda Pharmaceutical Co ’s upcoming earnings report date?
Takeda Pharmaceutical Co ’s upcoming earnings report date is Oct 30, 2025 which is in 90 days.
How were Takeda Pharmaceutical Co ’s earnings last quarter?
Takeda Pharmaceutical Co released its earnings results on Jul 30, 2025. The company reported $0.533 earnings per share for the quarter, beating the consensus estimate of $0.333 by $0.2.
Is Takeda Pharmaceutical Co overvalued?
According to Wall Street analysts Takeda Pharmaceutical Co ’s price is currently Undervalued.
Does Takeda Pharmaceutical Co pay dividends?
Takeda Pharmaceutical Co pays a Semiannually dividend of $0.687 which represents an annual dividend yield of 4.87%. See more information on Takeda Pharmaceutical Co dividends here
What is Takeda Pharmaceutical Co ’s EPS estimate?
Takeda Pharmaceutical Co ’s EPS estimate is 0.3.
How many shares outstanding does Takeda Pharmaceutical Co have?
Takeda Pharmaceutical Co has 1,590,962,600 shares outstanding.
What happened to Takeda Pharmaceutical Co ’s price movement after its last earnings report?
Takeda Pharmaceutical Co reported an EPS of $0.533 in its last earnings report, beating expectations of $0.333. Following the earnings report the stock price went up 2.052%.
Which hedge fund is a major shareholder of Takeda Pharmaceutical Co ?
Currently, no hedge funds are holding shares in TKPHF
Company Description
Takeda Pharmaceutical Co
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan, the United States, Europe, Canada, Latin America, Russia, rest of Asia, and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab, Alofisel, Dexilant, Natpara, Adynovate/Adynovi, Takhzyro, Livtencity, Elaprase, Replagal, Advate, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, Velcade, Leuplin/Enantone, Adcetris, Vyvansese, Trintellix, and Alunbrig brands. Takeda Pharmaceutical Company Limited has out-licensing agreement with Neurocrine Biosciences, Inc.; collaborations and in-licensing agreements with the University of Texas MD Anderson Cancer Center, Arrowhead Pharmaceuticals Inc., and Ovid Therapeutics Inc.; and collaboration with Evox Therapeutics Ltd., as well as a licensing agreement with ProThera Biologics Inc. It also has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, Selecta Biosciences, BridGene Biosciences, Skyhawk Therapeutics, and StrideBio; and strategic alliances with Egle Therapeutics SAS; Evotec SE; Neurocrine Biosciences, Inc.; Carmine Therapeutics; KSQ Therapeutics; and Anima Biotech. Takeda Pharmaceutical Company Limited was founded in 1781 and is headquartered in Tokyo, Japan.
TKPHF Company Deck
TKPHF Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
Takeda demonstrated strong performance and growth in its product portfolio and pipeline, with positive financial results and shareholder returns. However, challenges from VYVANSE's loss of exclusivity, ENTYVIO's U.S. market issues, and higher taxes slightly dampened the overall results.Read More>TKPHF Stock 12 Month Forecast
Average Price Target
$34.24
▲(27.76%Upside)
Technical Analysis
Sumitomo Dainippon Pharma Co
―
Eisai Co
―
Hisamitsu Pharmaceutical Co
―
Shionogi & Co
―
Tsumura & Co
―
Ownership Overview
0.05% Insiders
7.31% Mutual Funds
<0.01% Other Institutional Investors
82.36% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---